Світ медицини та біології, 2021, № 4 (78)

Постійне посилання зібрання

https://repository.pdmu.edu.ua/handle/123456789/17404

Переглянути

Перегляд Світ медицини та біології, 2021, № 4 (78) за Ключові слова "616.36-006-085"

Зараз показуємо 1 - 1 з 1
  • Ескіз недоступний
    Документ
    The role of L-ornithine-L-aspartate in prophylaxis of cytostatic-induced liver injury in patients with multiple myeloma
    (Полтавський державний медичний університет, 2021) Maslova, G. S.; Skrypnyk, R. I.; Skrypnyk, I. N.; Маслова, Ганна Сергіївна; Скрипник, Роман Ігорович; Скрипник, Ігор Миколайович
    The paper presents the findings of our studies on the assessment of the effectiveness of L-ornithine-L-aspartate in the prophylactic of chemotherapy-induced liver injury in patients with multiple myeloma. 24 patients with multiple myeloma were examined (11 females and 13 males, ages 46–78). The condition assessment was conducted twice: before chemotherapy and after 3 courses of chemotherapy. Patients were analyzed for the following biochemical parameters: the activity of alanine and asparagines aminotransferases, gamma-glutamyltranspeptidase, alkaline phosphatase, total bilirubin, total protein, creatinine, urea, total blood calcium level. Depending on the inclusion of L-ornithine-L-aspartate as an adjuvant treatment, patients were divided into 2 groups: group I (n=12) – patients with multiple myeloma, who underwent only chemotherapy; group II (n=12) – patients with multiple myeloma, who during chemotherapy received L-ornithine-L-aspartate at a dose of 10 g/day intravenously for 10 days, then 5 g 2 twice a day for 20 days. Group ІІІ (n=20) the control group, included 20 practically healthy persons. It was established, that application of L-ornithine-L-aspartate as an adjuvant treatment in patients with multiple myeloma that undergo chemotherapy provides the effective prophylactic of pathological alterations in liver and kidney functional state.